These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 3779714)
1. Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity. Wakamiya N; Wang YL; Imai H; Gu HX; Ueda S; Kato S Cancer Immunol Immunother; 1986; 23(2):125-9. PubMed ID: 3779714 [TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of two kinds of tumor vaccine modified with vaccinia virus. Ito T; Okabayashi M; Osada Y; Wakamiya N; Kato S In Vivo; 1988; 2(5):325-9. PubMed ID: 2979853 [TBL] [Abstract][Full Text] [Related]
3. Additional evidence for the augmented induction of tumor-specific resistance in vaccinia virus-primed mice by immunization with vaccinia virus-modulated syngeneic tumor cells. Ueda S; Wakamiya N; Wu KS; Kato S; Fujiwara H; Hamaoka T Biken J; 1984 Mar; 27(1):1-7. PubMed ID: 6385960 [TBL] [Abstract][Full Text] [Related]
4. The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo. Yoshioka T; Fukuzawa M; Takai Y; Wakamiya N; Ueda S; Kato S; Fujiwara H; Hamaoka T Cancer Immunol Immunother; 1986; 21(3):193-8. PubMed ID: 2938736 [TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of vaccinia virus-modified tumor cell vaccine. Ito T; Wang DQ; Maru M; Nakajima K; Kato S; Kurimura T; Wakamiya N Cancer Res; 1990 Nov; 50(21):6915-8. PubMed ID: 2208158 [TBL] [Abstract][Full Text] [Related]
6. Prevention of syngeneic tumor growth in vaccinia virus-primed mice by immunization with vaccinia virus-modulated tumor cells. Wu KS; Ueda S; Sakaue Y; Ohashi Y; Ikuta K; Sugano T; Kato S Biken J; 1981 Dec; 24(4):153-8. PubMed ID: 7346041 [TBL] [Abstract][Full Text] [Related]
7. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity. Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424 [TBL] [Abstract][Full Text] [Related]
8. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses. Takai Y; Kosugi A; Yoshioka T; Tomita S; Fujiwara H; Hamaoka T J Immunol; 1985 Jan; 134(1):108-13. PubMed ID: 3155458 [TBL] [Abstract][Full Text] [Related]
9. The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells. Shimizu Y; Fujiwara H; Ueda S; Wakamiya N; Kato S; Hamaoka T Eur J Immunol; 1984 Sep; 14(9):839-43. PubMed ID: 6236991 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of tumor-bearing mice utilizing virus help. Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y Cancer Immunol Immunother; 1988; 27(3):223-7. PubMed ID: 3263207 [TBL] [Abstract][Full Text] [Related]
11. [Significance of priming of hosts with virus in the tumor-specific immunotherapy model utilizing virus-reactive helper T cell activity]. Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):1007-14. PubMed ID: 2528599 [TBL] [Abstract][Full Text] [Related]
12. T-T cell interaction in the in vitro induction of delayed-type hypersensitivity (DTH) responses: demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of DTH responses. Kosugi A; Takai Y; Ogata M; Fujiwara H; Hamaoka T J Leukoc Biol; 1985 May; 37(5):629-39. PubMed ID: 3156939 [TBL] [Abstract][Full Text] [Related]
14. Tumor cells treated with vaccinia virus can activate the alternative pathway of mouse complement. Wakamiya N; Okada N; Wang YL; Ito T; Ueda S; Kato S; Okada H Jpn J Cancer Res; 1989 Aug; 80(8):765-70. PubMed ID: 2511185 [TBL] [Abstract][Full Text] [Related]
15. The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. Lai CF; Gong SC; Esteban M J Virol; 1991 Oct; 65(10):5631-5. PubMed ID: 1654459 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of the rat 13762SC mammary adenocarcinoma by vaccinia virus augmentation of tumor immunity. Archer TP; Bretscher P; Ziola B Clin Exp Metastasis; 1990; 8(6):519-32. PubMed ID: 2225567 [TBL] [Abstract][Full Text] [Related]
17. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies. Kawase I; Komuta K; Ogura T; Fujiwara H; Hamaoka T; Kishimoto S Cancer Res; 1985 Apr; 45(4):1663-8. PubMed ID: 3978634 [TBL] [Abstract][Full Text] [Related]
18. Protective immune responses to the E and NS1 proteins of Murray Valley encephalitis virus in hybrids of flavivirus-resistant mice. Hall RA; Brand TN; Lobigs M; Sangster MY; Howard MJ; Mackenzie JS J Gen Virol; 1996 Jun; 77 ( Pt 6)():1287-94. PubMed ID: 8683218 [TBL] [Abstract][Full Text] [Related]
19. Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism. Sato S; Fujiwara H; Kosugi A; Hamaoka T Cancer Immunol Immunother; 1987; 24(2):121-6. PubMed ID: 3493845 [TBL] [Abstract][Full Text] [Related]
20. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers. Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]